

依折麦布药物报告

ezetimibe Drug Report

摘要信息


药物英文名	ezetimibe
药物中文名	依折麦布
药物别名	Zetia; SCH58235
原研单位	Essex (Originator), Schering-Plough (Originator), Merck & Co. (Licensee)
全球最高状态	2002年批准上市
中国是否上市	是

药物概述

依折麦布 (Ezetimibe) 由默沙东 (MSD) 研发, 于2002年10月25日获美国食品药品监督管理局 (FDA) 批准, 之后于2007年4月18日获日本医药品医疗器械综合机构 (PMDA) 批准, 由默沙东上市销售, 商品名为Zetia。依折麦布是一种胆固醇吸收抑制剂。它抑制了小肠中胆固醇的吸收, 降低肝脏细胞里胆固醇的含量, 促使循环中胆固醇的吸收增加, 从而降低了血液中胆固醇含量。主要用于辅助饮食治疗原发性高脂血症, 混合型高脂血症, 纯合子家族性高胆固醇血症和纯合子谷甾醇血症 (植物固醇血症)。Zetia为口服片剂, 每片含10 mg 依折麦布。推荐剂量为每日1次, 每次10 mg, 随餐或空腹均可。

API信息

结构式



化学名称: (3R,4S)-1-(p-fluorophenyl)-3-[(3S)-3-(p-fluorophenyl)-3-hydroxypropyl]-4-(p-hydroxyphenyl)-2-azetidinone

CAS登记号: 163222-33-1

分子式: C₂₄H₂₁F₂NO₃

分子量: 409.4299

药理作用

ATC分类

C10AX09 心血管系统 > 血脂调节剂 > 血脂调节剂, 单方 > 其它血脂调节剂

作用靶点

Niemann-Pick C1-like protein-1 inhibitor

美国上市情况(11条)

申请号	商标名	活性成分	剂型/给药途径	批准时间	申请机构
021445	ZETIA	EZETIMIBE	TABLET;ORAL	2002-10-25	MSD INTL GMBH
201790	EZETIMIBE	EZETIMIBE	TABLET; ORAL	2013-08-07	MYLAN PHARMS INC
078560	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2015-06-26	GLENMARK PHARMS LTD
208803	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	AMNEAL PHARMS CO
208332	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	APOTEX INC
200831	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	WATSON LABS INC
207311	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	OHM LABS INC
078724	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	TEVA PHARMS USA
204331	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	ZYDUS PHARMS USA INC
203931	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-06-12	SANDOZ INC
209838	EZETIMIBE	EZETIMIBE	TABLET;ORAL	2017-08-25	

欧盟上市情况(51条)

隐藏

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
DE/ H/0 396 / /	EZETROL 10 mg Tabletten	ezetimi be 10 mg	Tab let	Merck Sharp & Dohme Ltd. Hertford Road GB-EN11 9BU Hoddesdon, Hertfordshire United Kingdom	2003-03-04
DE/ H/0 399 / /	EZETIMIBE MSD-SP 10 mg Tabletten	ezetimi be 10 mg	Tab let	Merck Sharp & Dohme Ltd. Hertford Road GB-EN11 9BU Hoddesdon, Hertfordshire United Kingdom	2003-03-04
DE/ H/0 397 / /	ZIENT 10 mg Tabletten	ezetimi be 10 mg	Tab let	Merck Sharp & Dohme Ltd. Hertford Road GB-EN11 9BU Hoddesdon, Hertfordshire United Kingdom	2003-03-04
DE/ H/0 398 / /	VIEMM 10 mg Tabletten	ezetimi be 10 mg	Tab let	Merck Sharp & Dohme Ltd. Hertford Road GB-EN11 9BU Hoddesdon, Hertfordshire United Kingdom	2003-03-04

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
SI/ H/0 105 /	Ezoleta 10 mg tablets	ezetimi be 10 mg	Tab let	Krka, d.d., Novo mesto, Slovenia	2009-10-08
HU/ H/0 217 /	Ezetimibe- Teva	ezetimi be 10 mg	Tab let	TEVA Magyarország Zrt Rákóczi út 70-72, Budapest, H-1074 Hungary	2010-01-07
DK/ H/1 759 /	Coltowan	ezetimi be 10 mg	Tab let	Gedeon Richter Plc. 1103 Budapest Gyömroi út 19-21 Hungary	2010-09-16
HU/ H/0 318 /	Lipobon	ezetimi be 10 mg	Tab let	EGIS Pharmaceuticals Plc. H-1106 Budapest, Keresztúri út 30-38. registry@egis.hu	2012-02-29
AT/ H/0 441 /	Ezetimib Sandoz 10 mg - Tabletten	ezetimi be 10 mg	Tab let	Sandoz GmbH Biochemiestrasse 10 6250 Kundl	2013-02-15
AT/ H/0 442 /	Ezetimib Hexal 10 mg - Tabletten	ezetimi be 10 mg	Tab let	Hexal Pharma GmbH Stella-Klein-Löw Weg 17 1020 Wien	2013-02-15
CZ/ H/0 219 /	Ezen 10 mg	ezetimi be 10 mg	Tab let	Zentiva, k.s., U kabelovny 130 102 37 Praha 10 - Dolní Měcholupy The Czech Republic	2013-03-13
DE/ H/3 732 /	EZETIMIB BASICS 10 mg Tabletten	ezetimi be 10 mg	Tab let	Basics GmbH Hemmelrather Weg 201 51377 Leverkusen Germany	2014-01-23
NL/ H/2 923 /	Ezetimibe Mylan 10 mg	ezetimi be 10 mg	Tab let	Mylan B.V. Dieselweg 25 3752 LB Bunschoten The Netherlands	2014-05-20
DK/ H/2 317 /	Ezetimib Richter	ezetimi be 10 mg	Tab let	Gedeon Richter Plc. Gyömrői út 19-21 Budapest 1103 Hungary	2014-06-11
NL/ H/3 139 /	Ezetimibe Glenmark 10 mg Tabletten	ezetimi be 10 mg	Tab let	Glenmark Pharmaceuticals Europe Limited Laxmi House, 2B Draycott Avenue, Kenton, Harrow, Middlesex HA3 0BU United Kingdom	2015-05-08
NL/ H/3 191 /	Ezetimibe Uriach 10 mg tablets	ezetimi be 10 mg	Tab let	J.Uriach y Compañía, S.A. Av. Camí Reial, 51-57 08184 Palau-Solità i Plegamans (Barcelone) Spain	2015-05-26

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
DK/ H/2 467 /	Carditimib	ezetimi be 10 mg	Tab let	Gedeon Richter Plc. Gyömrő 'i út 19-21 1103 Budapest Hungary	2015-11-18
DK/ H/2 444 /	Intestat	ezetimi be 10 mg	Tab let	Gedeon Richter Plc. Gyömrő 'i út 19-21 1103 Budapest Hungary	2015-11-18
ES/ H/0 329 /	Ezetimiba Accord 10mg tablets	ezetimi be 10 mg	Tab let	Accord Healthcare Limited Sage house, 319 Pinner road, North Harrow, Middlesex, HA1 4HF, United Kingdom	2016-03-08
ES/ H/0 330 /	Ezetimiba astron	ezetimi be 10 mg	Tab let	Astron Research Ltd. Accord Healthcare Limited Sage house, 319 Pinner road, North Harrow, Middlesex, HA1 4HF, United Kingdom	2016-03-08
DE/ H/4 286 /	Ezetimib- ratiopharm	ezetimi be 10 mg	Tab let	Teva Nederland B.V. Swensweg 5 NL-2031 GA HAARLEM	2016-04-18
DE/ H/4 285 /	Ezetimib AbZ 10 mg	ezetimi be 10 mg		Teva Nederland B.V. Swensweg 5 NL-2031 GA HAARLEM	2016-04-18
NL/ H/3 516 /	Ezetimib CF	ezetimi be 10 mg	Tab let	STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel Germany	2016-07-27
NL/ H/3 731 /	Ezetimibe STADA 10 mg, tabletten	ezetimi be 10 mg	Tab let	Stada Arzneimittel AG Stadast. 2-18 Bad Vilbel 61118 Germany	2016-07-27
ES/ H/0 385 /	Ezetimibe Alter 10 mg tablets	ezetimi be 10 mg	Tab let	LABORATORIOS ALTER, S.A. C/ Mateo Inurria, 30 28036, Madrid Spain	2016-08-10
PT/ H/1 569 /	Ezetimiba Miril	ezetimi be 10 mg	Tab let	ToLife - Produtos Farmacêuticos, S.A.	2016-10-12
SI/ H/0 163 /	Ezetimibe Krka 10 mg tablets	ezetimi be 10 mg	Tab let	Krka, d.d., Novo mesto Å marjeÅjka cesta 6 8501 Novo mesto Slovenia	2016-10-18
SI/ H/0 168 /	Ezetimibe Krka 10 mg tablets	ezetimi be 10 mg	Tab let	Krka, d.d., Novo mesto Å marjeÅjka cesta 6 8501 Novo mesto Slovenia	2016-10-18

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
SI/ H/0 170 /	Ylerse 10 mg tablets	ezetimi be 10 mg	Tab let	Krka, d.d., Novo mesto Å marjeÅjka cesta 6 8501 Novo mesto Slovenia	2016-10-18
DE/ H/4 417 /	Ezetimib Heumann 10 mg Tabletten	ezetimi be 10 mg	Tab let	Torrent Pharma GmbH Südwestpark 50 D-90449 Nürnberg	2016-10-19
NL/ H/3 473 /	Ezetimibe Apotex 10 mg, tablets	ezetimi be 10 mg	Tab let	Apotex Europe B.V. Darwinweg 20 2333 CR Leiden Netherlands	2016-10-26
NL/ H/3 620 /	Ezetimibe Apotex 10 mg, tablets	ezetimi be 10 mg	Tab let	Apotex Europe B.V. Darwinweg 20 2333 CR Leiden Netherlands	2016-10-26
DK/ H/2 563 /	Ezetimibe Actavis	ezetimi be 10 mg	Tab let	Actavis Group PTC ehf., Reykjavíkurvegi 76-78 220 Hafnarfjörður Iceland	2016-12-20
DK/ H/2 564 /	Colezen	ezetimi be 10 mg	Tab let	SF Group	2016-12-20
DK/ H/2 565 /	Mibecol	ezetimi be 10 mg	Tab let	SF Group	2016-12-20
DK/ H/2 572 /	Ezetimibe DOC Generici	ezetimi be 10 mg	Tab let	DOC Generici Srl Via Turati 40, Milano 20121 Italia	2016-12-20
DK/ H/2 573 /	Ezetimibe Alchemia	ezetimi be 10 mg	Tab let	Alchemia Ltd	2016-12-20
DK/ H/2 574 /	Alchetmibel	ezetimi be 10 mg	Tab let	Alchemia Limited, 5th Floor, 86 Jermyn Street, London SW1Y 6AW United Kingdom	2016-12-20
DK/ H/2 630 /	Ezetimib Sigillata	ezetimi be 10 mg	Tab let	Sigillata Limited Suite 23, Park Royal House 23 Park Royal Rd United Kingdom NW10 7JH London United Kingdom	2016-12-20
DK/ H/2 661 /	Zertya	ezetimi be 10 mg	Tab let	Pharmahten S.A. 6 Deveniakon Str 153 51 Pallini Attiki Greece	2016-12-20

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
NL/ H/3 693 /	Ezegal 10 mg omhulde tabletten	ezetimi be 10 mg	Coa ted tabl et	Laboratoires SMB SA 26-28, rue de la Pastorale B- 1080 Bruxelles	2017-02-08
UK/ H/6 322 /	Ezetimibe 10mg tablets	ezetimi be 10 mg	Tab let	LUPIN (EUROPE) LIMITED VICTORIA COURT BEXTON ROAD KNUTSFORD WA16 0PF UNITED KINGDOM	2017-05-04
PL/ H/0 431 /	Ezetimibe Adamed	ezetimi be 10 mg	Tab let	Adamed Sp. z o.o. Pienkow 149 05-152 Czosnow Poland	2017-05-09
PL/ H/0 445 /	Ezetimibe +pharma	ezetimi be 10 mg	Tab let	+pharma arzneimittel gmbh Hafnerstrasse 211 Graz 8054 Austria	2017-05-09
PT/ H/1 655 /	Eztimibe Rafarm	ezetimi be 10 mg	Tab let	Rafarm, S.A.	2017-05-17
FI/ H/0 915 /	Ezetimib Amneal	ezetimi be 10 mg	Tab let	Amneal Pharma Europe Limited 70 Sir John Rogerson's Quay Dublin 2 Ireland	2017-05-22
FI/ H/0 916 /	Ezelicon	ezetimi be 10 mg	Tab let	Laboratorios Liconsa S.A. Gran Via Carlos III, 98, 7th floor 08028 Barcelona Spain	2017-05-22
FI/ H/0 917 /	Ezetimib Liconsa	ezetimi be 10 mg	Tab let	Laboratorios Liconsa S.A. Gran Via Carlos III, 98, 7th floor 08028 Barcelona Spain	2017-05-22
PT/ H/1 684 /	Eztimibe Venifar	ezetimi be 10 mg	Tab let	Venifar, Ltd.	2017-06-07
DK/ H/2 700 /	CILDAR	ezetimi be 10 mg	Tab let	MEDOCHEMIE HELLAS SA 6, Pasteur street, Ampelokipi Athens Greece	2017-08-15
DE/ H/5 110 /	Ezetimib Micro Labs 10 mg Tabletten	ezetimi be 10 mg	Tab let	Micro Labs GmbH Lyoner StraÙe 14 60528 Frankfurt Germany	2017-10-04

日本上市情况(3条)

商标名	活性成份	申请类型	申请公司	批准日期
-----	------	------	------	------

Zetia Tablets 10 mg	Ezetimibe	Approval	(Schering-plough K.K.)	2007/04/18
ゼチーア錠10mg	Ezetimibe		製造販売元 / MSD株式会社	1986/03
ゼチーア錠10mg	Ezetimibe		製造販売元 / MSD株式会社 販売元 / バイエル薬品株式会社	1992/08

主要上市国家/地区(63条)

隐藏

国家名称	上市公司	商标名	活性成分	适应症	状态
Arg	Phoenix	Acotral	Ezetimibe	高胆固醇血症	
Arg	Lazar	Alin	Ezetimibe	高胆固醇血症	
Arg	Bernabo	Alipas	Ezetimibe	高胆固醇血症	
Arg	Beta	Cerclerol	Ezetimibe	高胆固醇血症	
Arg	LKM	Cetrakam	Ezetimibe	高胆固醇血症	
Arg	Gador	Coracil	Ezetimibe	高胆固醇血症	
India	Unichem	Ezetib	Ezetimibe	高胆固醇血症	
Arg.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Austral.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Austria	Aesca	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Austria	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Belg.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Braz.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Canad.	Merck Frosst	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Canad.	Schering	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Chile	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Cz.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Denm.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Fin.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Fr.	MSD-Chibret	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Ger.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Gr.	Vianex (Βιανεξ)	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Hong Kong	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Hong Kong	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Hung.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Indon.	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Irl.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	

国家名称	上市公司	商标名	活性成分	适应症	状态
Israel	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Malaysia	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Malaysia	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Mex.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
NZ	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Neth.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Norw.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Philipp.	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Port.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Rus.	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
S.Afr.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Singapore	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Singapore	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Spain	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Swed.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Swed.	Schering-Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Switz.	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Thai.	Schering- Plough	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
UK	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
Venez	MSD	Ezetrol	Ezetimibe	动脉粥样硬化;高胆固醇血症	
India*	Glenmark	Ezzicad	Ezetimibe	高胆固醇血症	可能已退市
India	Ipca	Imbibe	Ezetimibe	Hyperlipidaemias	
Arg	Roemmers	Ixacor	Ezetimibe	高胆固醇血症	
Arg	Casasco	Nalecol	Ezetimibe	高胆固醇血症	
Arg	Klonal	Sinterol	Ezetimibe	高胆固醇血症	
Arg	Elea	Trilip	Ezetimibe	高胆固醇血症	
Arg	Ivax	Vadel	Ezetimibe	Hyperlipidaemias	
Arg.	Schering-Plough	Zetia	Ezetimibe	高胆固醇血症	
Braz.	Mantecorp	Zetia	Ezetimibe	高胆固醇血症	
USA	Merck	Zetia	Ezetimibe	高胆固醇血症	
USA	Schering- Plough	Zetia	Ezetimibe	高胆固醇血症	
Venez	Schering-Plough	Zetia	Ezetimibe	高胆固醇血症	
Chile	Essex	Zient	Ezetimibe	动脉粥样硬化;高胆固醇血症;谷固醇血症	
Cz.	MSD	Zient	Ezetimibe	动脉粥样硬化;高胆固醇血症;谷固醇血症	

国家名称	上市公司	商标名	活性成分	适应症	状态
Mex.	Schering-Plough	Zient	Ezetimibe	动脉粥样硬化;高胆固醇血症;谷固醇血症	
Venez	Schering- Plough	Zient	Ezetimibe	动脉粥样硬化;高胆固醇血症;谷固醇血症	

中国上市情况(3条)

药品名称	批准文号	药品规格	生产厂商	国产厂家数量	是否医保
依折麦布片	H20160181	10mg	MSD International GmbH (Singapore Branch)	新加坡进口	
依折麦布片	H20171017	10mg	MSD International GmbH (Singapore Branch)	新加坡进口	
依折麦布片	J20171023	10mg	MSD International GmbH (Singapore Branch)	新加坡进口	

中国注册申报情况(91条)

隐藏

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
J0300542	依折麦布片	进口	3.1	2003-05-04	MSP 新加坡公司	已发批件	2003-11-27	批准临床
JXHS0500036	依折麦布片	进口	3.1	2005-04-27	MSP新加坡公司	制证结束待发送-已批准	2006-04-19	批准进口
JYHB0700587	依折麦布片	补充申请		2007-05-24	Schering-Plough Labo N.V.	已发批件	2007-12-29	批准补充
JYHB0700629	依折麦布片	补充申请		2007-05-30	MSP SINGAPORE COMPANY LLC	制证完毕 - 已发批件	2008-04-14	批准补充
JYHB0901010	依折麦布片	补充申请		2009-11-25	MSP Singapore Company, LLC	制证完毕 - 已发批件	2010-06-07	批准补充
JXHS1100053	依折麦布	进口		2011-05-11	Teva API India Limited	制证完毕 - 已发批件	2012-06-29	终止审批程序
JXHL1200201	依折麦布	进口		2012-06-29	印思特实验室	制证完毕 - 已发批件	2016-05-24	批准临床
CXHS1200189	依折麦布	新药	3.1	2012-08-22	江苏豪森医药集团连云港宏创医药有限公司	制证完毕 - 已发批件	2014-01-07	批准临床
CYHS1200932	依折麦布片	仿制	6	2012-10-23	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2014-01-07	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHL12003 91	依折麦布	进口		2012-12- 17	Teva API India Limited	制证完毕 - 已 发批件	2015-11-26	批准临床
CYHS1300 095	依折麦布 片	仿制	6	2013-04- 22	南京先声 东元制药 有限公司	制证完毕 - 已 发批件	2015-12-24	批准临床
CXHS1300 020	依折麦布	新药	3.1	2013-04- 22	南京先声 东元制药 有限公司	制证完毕 - 已 发批件	2015-12-15	批准临床
CYHS1300 171	依折麦布 片	仿制	6	2013-06- 20	南京柯菲 平盛辉制 药有限公 司	制证完毕 - 已 发批件	2015-11-25	批准临床
CXHS1300 024	依折麦布	新药	3.1	2013-06- 21	四川制药 制剂有限 公司	制证完毕 - 已 发批件	2015-12-15	不批准
CXHS1300 126	依折麦布	新药	3.1	2013-06- 28	重庆圣华 曦药业股 份有限公 司	制证完毕 - 已 发批件	2015-12-24	批准临床
CYHS1300 686	依折麦布 片	仿制	6	2013-07- 11	重庆圣华 曦药业股 份有限公 司	制证完毕 - 已 发批件	2015-12-24	批准临床
CYHS1300 433	依折麦布 片	仿制	6	2013-08- 02	深圳致君 制药有限 公司	制证完毕 - 已 发批件	2016-08-12	批准临床
CXHL1300 647	依折麦布	新药	3.1	2013-08- 07	重庆华邦 胜凯制药 有限公司	制证完毕 - 已 发批件	2016-01-14	批准临床
CYHS1301 003	依折麦布 片	仿制	6	2013-09- 02	重庆华邦 制药有限 公司	制证完毕 - 已 发批件	2016-01-14	批准临床
CYHS1301 034	依折麦布 片	仿制	6	2013-10- 15	四川制药 制剂有限 公司	制证完毕 - 已 发批件	2015-12-15	批准临床
CYHS1301 216	依折麦布 片	仿制	6	2013-12- 11	重庆福安 药业集团 庆余堂制 药有限公 司	制证完毕 - 已 发批件	2016-01-22	批准临床
CXHL1300 822	依折麦布	新药	3.1	2013-12- 11	重庆福安 药业(集 团)股份 有限公司	制证完毕 - 已 发批件	2016-01-22	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JYHB1301838	依折麦布片	补充申请		2014-01-24	MSP Singapore Company, LLC	制证完毕 - 已发批件	2014-08-27	
JXHL1400033	依折麦布	进口		2014-02-19	华科医药知识产权咨询中心	在审评审批中	2014-02-17	
CYHS1302093	依折麦布片	仿制	6	2014-03-19	武汉启瑞药业有限公司	制证完毕 - 已发批件	2016-01-29	批准临床
CXHB1400031	依折麦布等32个品种	补充申请		2014-04-02	福安药业(集团)股份有限公司	审批完毕	2014-08-20	
CYHS1300491	依折麦布片	仿制	6	2014-04-09	山东罗欣药业股份有限公司	制证完毕 - 已发批件	2016-01-28	批准临床
CXHS1300091	依折麦布	新药	3.1	2014-04-09	山东罗欣药业股份有限公司	制证完毕 - 已发批件	2016-01-28	批准临床
CXHS1400010	依折麦布	新药	3.1	2014-04-11	江西施美制药有限公司	制证完毕 - 已发批件	2016-02-04	批准临床
CXHS1400068	依折麦布	新药	3.1	2014-04-14	湖南有色凯铂生物药业有限公司	制证完毕 - 已发批件	2016-03-01	批准临床
CXHS1300257	依折麦布	新药	3.1	2014-04-21	常州制药厂有限公司	制证完毕 - 已发批件	2016-01-28	批准临床
CYHS1301700	依折麦布片	仿制	6	2014-04-28	浙江华海药业股份有限公司	制证完毕 - 已发批件	2016-02-19	批准临床
CXHS1400022	依折麦布	新药	3.1	2014-06-06	湖南方盛制药股份有限公司	制证完毕 - 已发批件	2016-01-29	批准临床
CYHS1400074	依折麦布片	仿制	6	2014-06-06	湖南方盛制药股份有限公司	制证完毕 - 已发批件	2016-01-29	批准临床
CYHS1400497	依折麦布片	仿制	6	2014-06-18	扬子江药业集团广州海瑞药业有限公司	制证完毕 - 已发批件	2016-01-28	批准临床
CXHS1300307	依折麦布	新药	3.1	2014-06-23	浙江华海药业股份有限公司	制证完毕 - 已发批件	2016-02-19	批准临床


受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHL1400118	依折麦布	进口		2014-06-23	格兰马克有限公司	制证完毕 - 已发批件	2016-01-15	批准临床
CYHS1400333	依折麦布片	仿制	6	2014-07-03	北京万生药业有限责任公司	制证完毕 - 已发批件	2016-01-28	批准临床
CYHS1400411	依折麦布片	仿制	6	2014-07-24	海南皇隆制药股份有限公司	制证完毕 - 已发批件	2016-02-04	批准临床
CYHS1400214	依折麦布片	仿制	6	2014-07-30	石药集团欧意药业有限公司	制证完毕 - 已发批件	2016-02-04	批准临床
JXHL1400268	依折麦布片	进口		2014-08-07	吉瑞大药厂	制证完毕 - 已发批件	2016-10-18	批准临床
CYHS1400471	依折麦布片	仿制	6	2014-08-11	海南锦瑞制药有限公司	制证完毕 - 已发批件	2016-03-01	批准临床
CYHS1400037	依折麦布片	仿制	6	2014-08-26	江西施美制药有限公司	制证完毕 - 已发批件	2016-02-04	批准临床
CYHS1400460	依折麦布片	仿制	6	2014-09-03	北京协和药厂	制证完毕 - 已发批件	2016-02-19	批准临床
CYHS1301461	依折麦布片	仿制	6	2014-09-09	常州制药厂有限公司	制证完毕 - 已发批件	2016-02-03	批准临床
CXHL1401011	依折麦布	新药	3.1	2014-09-11	湖北华世通生物医药科技有限公司	制证完毕 - 已发批件	2016-02-19	批准临床
CYHS1401033	依折麦布片	仿制	6	2014-09-28	湖北华世通潜龙药业有限公司	制证完毕 - 已发批件	2016-02-04	批准临床
CYHS1400306	依折麦布片	仿制	6	2014-10-16	华润赛科药业有限责任公司	制证完毕 - 已发批件	2016-02-19	批准临床
CXHS1400233	依折麦布	新药	3.1	2014-11-02	连云港宏创药业有限公司	制证完毕 - 已发批件	2016-12-30	
CXHS1400209	依折麦布	新药	3.1	2014-11-03	齐鲁天和惠世制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CYHS1490077	依折麦布片	仿制	6	2014-11-03	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2016-03-17	企业撤回
CXHL1401576	依折麦布	新药	3.1	2014-12-19	廊坊高博京邦制药有限公司	制证完毕 - 已发批件	2016-05-12	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CYHS1401374	依折麦布片	仿制	6	2015-01-07	西安葛蓝新通制药有限公司	制证完毕 - 已发批件	2016-05-04	批准临床
CXHL1401498	依折麦布	新药	3.1	2015-01-07	陕西大生制药科技有限公司	制证完毕 - 已发批件	2016-05-04	批准临床
CYHS1401409	依折麦布片	仿制	6	2015-01-14	云南白药集团大理药业有限责任公司	制证完毕 - 已发批件	2016-02-18	批准临床
CXHL1401903	依折麦布	新药	3.1	2015-02-26	天方药业有限公司	制证完毕 - 已发批件	2016-03-01	批准临床
CXHL1402021	依折麦布	新药	3.1	2015-02-26	武汉长联来福制药股份有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CXHS1500010	依折麦布	新药	3.1	2015-03-24	浙江天宇药业股份有限公司	制证完毕 - 已发批件	2016-05-12	批准临床
CYHS1401741	依折麦布片	仿制	6	2015-05-15	天方药业有限公司	制证完毕 - 已发批件	2016-03-01	批准临床
CXHL1500277	依折麦布	新药	3.1	2015-05-25	江苏兰健药业有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CXHL1500503	依折麦布	新药	3.1	2015-05-25	常州亚邦制药有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CXHL1500834	依折麦布	新药	3.1	2015-07-08	山东铂源药业有限公司	制证完毕 - 已发批件	2016-07-14	批准临床
CXHL1401828	依折麦布	新药	3.1	2015-08-04	上海现代制药股份有限公司	制证完毕 - 已发批件	2016-06-27	批准临床
CXHL1501404	依折麦布	新药	3.1	2015-08-20	武汉武药制药有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CYHS1500444	依折麦布片	仿制	6	2015-09-06	华润双鹤药业股份有限公司	制证完毕 - 已发批件	2016-05-12	批准临床
CYHS1500603	依折麦布片	仿制	6	2015-09-16	苏州中化药品工业有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CXHL1501207	依折麦布	新药	3.1	2015-09-18	山东新时代药业有限公司	制证完毕 - 已发批件	2016-10-24	批准临床
CYHS1500492	依折麦布片	仿制	6	2015-09-21	北京利龄恒泰药业有限公司	制证完毕 - 已发批件	2016-05-12	批准临床


受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CXHL1500896	依折麦布	新药	3.1	2015-09-21	成都恒瑞制药有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CXHL1501541	依折麦布	新药	3.1	2015-09-22	浙江普洛得邦制药有限公司	制证完毕 - 已发批件	2016-09-03	批准临床
CYHS1401677	依折麦布片	仿制	6	2015-09-25	上海现代制药股份有限公司	制证完毕 - 已发批件	2016-06-27	批准临床
CYHS1500737	依折麦布片	仿制	6	2015-10-08	成都恒瑞制药有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CYHS1501141	依折麦布片	仿制	6	2015-10-13	昆药集团股份有限公司	制证完毕 - 已发批件	2016-08-04	批准临床
CXHL1500140	依折麦布	新药	3.1	2015-10-19	山西普德药业股份有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CXHL1500825	依折麦布	新药	3.1	2015-10-26	山东孔府制药有限公司	制证完毕 - 已发批件	2016-11-23	批准临床
CYHS1501053	依折麦布片	仿制	6	2015-11-13	远大医药(中国)有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CYHS1500775	依折麦布片	仿制	6	2015-11-27	杭州民生药业有限公司	制证完毕 - 已发批件	2016-07-21	批准临床
CXHL1502023	依折麦布	新药	3.1	2015-12-01	南京优科制药有限公司	制证完毕 - 已发批件	2017-09-20	批准临床
CYHS1500452	依折麦布片	仿制	6	2015-12-17	江苏亚邦强生药业有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CYHS1500130	依折麦布片	仿制	6	2015-12-24	山西普德药业股份有限公司	制证完毕 - 已发批件	2016-08-01	批准临床
CYHS1501026	依折麦布片	仿制	6	2016-01-05	华北制药股份有限公司	制证完毕 - 已发批件	2016-10-27	批准临床
CXHL1501360	依折麦布	新药	3.1	2016-01-05	华北制药华胜有限公司	制证完毕 - 已发批件	2016-10-27	批准临床
CYHS1501064	依折麦布片	仿制	6	2016-02-16	北京四环制药有限公司	制证完毕 - 已发批件	2016-05-19	批准临床
CXHL1502357	依折麦布	新药	3.1	2016-02-16	沈阳沃森药物研究所	制证完毕 - 已发批件	2017-02-13	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CXHL1502246	依折麦布胶囊	新药	5	2016-03-11	海南通用三洋药业有限公司	制证完毕 - 已发批件	2016-10-27	批准临床
CXHL1502013	依折麦布	新药	3.1	2016-04-15	南京华威医药科技开发有限公司	制证完毕 - 已发批件	2017-04-17	批准临床
CYHS1500942	依折麦布片	仿制	6	2016-04-20	山东新时代药业有限公司	制证完毕 - 已发批件	2016-10-27	批准临床
CYHS1500678	依折麦布片	仿制	6	2016-06-29	山东孔府制药有限公司	制证完毕 - 已发批件	2016-11-23	批准临床
JYHB1601289	依折麦布片	补充申请		2016-09-23	默沙东研发(中国)有限公司	制证完毕 - 已发批件	2017-01-04	批准临床
JYHB1700669	依折麦布片	补充申请		2017-05-13	默沙东研发(中国)有限公司	制证完毕 - 已发批件	2017-07-06	批准补充
JYHF1700046	依折麦布片	补充申请		2017-06-16	杭州默沙东制药有限公司	制证完毕 - 已发批件	2017-07-11	


申请类型



剂型



承办日期



药品标准(2条)

药品名称	标准来源	页码	查看全文/文件下载
依折麦布片	JX20030223		
Ezetimibe	USP39-NF34		查看

药品说明书(23条)

隐藏

药品名称	来源	更新时间	操作
------	----	------	----

依折麦布片	默沙东(中国)有限公司/MSD PHARMA (SINGAPORE) PTE. LTD.		查看全文下载1
依折麦布片	默沙东(中国)有限公司/MSD PHARMA (SINGAPORE) PTE. LTD.		下载1
ZETIA	MSD INTL GMBH	2002-10-25	
ZETIA	MSD INTL GMBH	2004-07-28	
ZETIA	MSD INTL GMBH	2005-03-29	
ZETIA	MSD INTL GMBH	2006-03-22	
ZETIA	MSD INTL GMBH	2006-11-06	
ZETIA	MSD INTL GMBH	2007-12-14	
ZETIA	MSD INTL GMBH	2008-02-14	
ZETIA	MSD INTL GMBH	2008-06-12	
ZETIA	MSD INTL GMBH	2009-07-23	
ZETIA	MSD INTL GMBH	2009-07-23	
ZETIA	MSD INTL GMBH	2011-08-12	
ZETIA	MSD INTL GMBH	2012-01-25	
ZETIA	MSD INTL GMBH	2004-07-28	
ZETIA	MSD INTL GMBH	2004-07-28	
ZETIA	MSD INTL GMBH	2005-03-10	
ZETIA	MSD INTL GMBH	2006-05-24	
ZETIA	MSD INTL GMBH	2006-01-27	
ZETIA	MSD INTL GMBH	2006-03-22	
ZETIA	MSD INTL GMBH	2008-06-12	
ZETIA	MSD INTL GMBH	2009-02-04	
ZETIA	MSD INTL GMBH	2014-10-30	

全球临床试验情况(254条)

[隐藏](#)

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D	Drug:Pegylated interferon alfa;Drug:Ezetimibe	Active, not recruiting	Hepatitis D, Chronic	Phase 2		2016-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Ezetimibe for Patients With Chronic Hepatitis D	Drug:Ezetimibe	Recruiting	Chronic Hepatitis D	Phase 2	Pakistan	2017-01-01
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C	Drug:Bempedoic acid 180mg;Drug:Ezetimibe 10mg;Drug:Atorvastatin 20mg;Other:Placebo	Recruiting	Hypercholesterolemia	Phase 2	United States	2017-01-01
Randomized Comparison of Efficacy and Safety of Lipid-lowering With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)	Drug:Rosuvastatin;Drug:Rosuvastatin plus ezetimibe	Recruiting	Cardiovascular Diseases;Cerebrovascular Disease;Peripheral Atherosclerotic Disease		Korea, Republic of	2017-03-15

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)	Drug:Bempedoic acid;Drug:Ezetimibe; Other:Placebo	Recruiting	Hypercholesterolemia;Atherosclerosis;Statin Adverse Reaction	Phase 3	United States	2016-12-01
Evaluation of Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia	Drug:alirocumab SAR236553;Drug:atorvastatin;Drug:rosuvastatin;Drug:fenofibrate;Drug:bezafibrate; Drug:ezetimibe;Drug:antiplatelets;Drug:anticoagulants	Recruiting	Hypercholesterolemia;Acute Coronary Syndrome	Phase 4	Japan	2016-11-01
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C	Drug:20mg ezetimibe;Drug:Placebo;Drug:40mg ezetimibe	Not yet recruiting	Chronic Hepatitis C	Phase 2	United States	2017-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia	Drug:Atorvastatin 20 mg;Drug:Cholestyramine 8 g;Drug:Omega-3 2g;Drug:Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg;Behavioral:Lifestyle modification	Recruiting	Hyperlipidemia		Korea, Republic of	2013-06-01
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia	Drug:alirocumab SAR236553 (REGN727);Drug:statins;Drug:ezetimibe;Drug:cholestyramine;Drug:fenofibrate;Drug:omega-3 fatty acids;Drug:nicotinic acid	Recruiting	Hypercholesterolemia	Phase 2	United States;Canada;Australia;France;Netherlands;Norway;Russian Federation;South Africa;Spain;Sweden	2016-09-01
Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe	Drug:Rosuvastatin and Ezetimibe morning or evening administration	Recruiting	Hypercholesterolemia	Phase 4	Poland	2016-03-01
Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	Drug:Ezetimibe	Recruiting	Hepatitis C	Phase 4	Chile	2013-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)	Drug:Rosuvastatin;Drug:Ezetimibe	Completed	Hypercholesterolemia	Phase 3	Korea, Republic of	2016-04-01
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)	Drug:Ezetimibe;Drug:Rosuvastatin	Active, not recruiting	Hypercholesterolemia;Familial Hypercholesterolemia	Phase 3		2016-05-18

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)	Drug:Ezetimibe 10 mg;Drug:Rosuvastatin 2.5 mg;Drug:Placebo for Ezetimibe;Drug:Placebo for Rosuvastatin	Completed	Hypercholesterolemia	Phase 3		2016-06-01
A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone	Drug:DP-R207;Drug:Rosuvastatin;Drug:Ezetimibe	Completed	Healthy Volunteers	Phase 1		2014-12-01
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia	Drug:alirocumab SAR236553 (REGN727);Drug:placebo for alirocumab;Drug:ezetimibe;Drug:placebo for ezetimibe;Drug:atorvastatin;Drug:rosuvastatin;Drug:simvastatin	Recruiting	Hypercholesterolemia	Phase 3	China;India;Thailand	2016-07-01
Randomized Trial Comparing Colesevelam vs. Ezetimibe	Drug:Colesevelam;Drug:Ezetimibe	Recruiting	Type 2 Diabetes Mellitus	Phase 4	Canada	2016-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)	Drug:ALIROCUMAB SAR236553 (REGN727);Drug:placebo;Drug:statins;Drug:ezetimibe;Drug:fenofibrate;Drug:nicotinic acid;Drug:omega-3 fatty acids	Active, not recruiting	Dyslipidemia	Phase 4	United States;Australia;Brazil;Finland;Germany;Israel;Italy;Kuwait;Lebanon;Norway;Sweden;Switzerland;Turkey;United Arab Emirates;United Kingdom	2016-03-01
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4	Biological:Evolocumab;Drug:Ezetimibe;Biological:Evolocumab;Drug:Ezetimibe	Recruiting	Hypercholesterolemia	Phase 3	Japan	2016-02-27
Ezetimibe and Atorvastatin Therapy on TCFA	Drug:Ezetimibe and Atorvastatin;Drug:Atorvastatin	Recruiting	Coronary Artery Disease	Phase 4	China	2015-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin	Drug:alirocumab SAR236553 (REGN727);Drug:placebo;Drug:atorvastatin;Drug:fenofibrate;Drug:bezafibrate;Drug:ezetimibe	Active, not recruiting	Hypercholesterolemia	Phase 3	Japan	2015-11-30
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)	Drug:Ezetimibe 10 mg;Drug:Atorvastatin 10 mg;Drug:Placebo for Ezetimibe 10 mg tablet;Drug:Placebo for Atorvastatin 10 mg capsule;Behavioral:Diet control/Daily Exercise	Completed	Hypercholesterolemia	Phase 3		2015-09-01
Efficacy and Safety of Simvastatin-Ezetimibe Combination Therapy Among Patients With SLE	Drug:Ezetimibe+Simvastatin Drug Combination	Enrolling by invitation	Atherosclerosis	Early Phase 1	China	2015-04-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males	Drug:CXA-10;Drug:pravastatin; Drug:Vytorin® (combination of simvastatin and ezetimibe)	Completed	Acute Kidney Injury	Phase 1	United States	2015-12-01
Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal	Drug:ezetimibe 10mg-simvastatin 40mg	Recruiting	Prostate Cancer	Early Phase 1	United States	2015-10-01
CKD-391 Pharmacokinetic Study Phase I	Drug:CKD-391;Drug:Atrovastatin and Ezetimibe combination therapy	Completed	Healthy	Phase 1		2015-08-01
CKD-391 Pharmacokinetic Study	Drug:CKD-391;Drug:Atrovastatin and Ezetimibe combination therapy	Completed	Healthy	Phase 1	Korea, Republic of	2015-07-01
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391	Drug:Atorvastatin10mg, Ezetimibe10mg;Drug:Atorvastatin10mg, Ezetimibe placebo;Drug:Atorvastatin20mg, Ezetimibe10mg;Drug:Atorvastatin20mg, Ezetimibe placebo;Drug:Atorvastatin40mg, Ezetimibe10mg;Drug:Atorvastatin40mg, Ezetimibe placebo	Completed	Hyperlipidemia	Phase 3	Korea, Republic of	2015-03-01
Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia	Drug:Simvastatin;Drug:Ezetimibe;Drug:Simvastatin + Ezetimibe	Completed	Dyslipidemia			2009-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers	Drug:Crestor+Ezetrol;Drug:Ezetrol;Drug:Crestor	Completed	Healthy	Phase 1		2014-12-01
CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers	Drug:1 (Lipitor®);Drug:1 (Ezetrol®);Drug:1 (Lipitor®, Ezetrol®);Drug:2 (Ezetrol®);Drug:2(Lipitor®, Ezetrol®);Drug:2 (Lipitor®);Drug:3(Lipitor®, Ezetrol®);Drug:3 (Lipitor®);Drug:3 (Ezetrol®);Drug:4 (Lipitor®);Drug:4(Lipitor®, Ezetrol®);Drug:4 (Ezetrol®);Drug:5 (Ezetrol®);Drug:5 (Lipitor®);Drug:5 (Lipitor®, Ezetrol®);Drug:6(Lipitor®, Ezetrol®);Drug:6 (Ezetrol®);Drug:6 (Lipitor®)	Completed	Healthy	Phase 1	Korea, Republic of	2014-11-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia	Drug:Evacetrapib;Drug:Ezetimibe;Drug:Atorvastatin;Drug:Placebo	Terminated	Hypercholesterolemia	Phase 3	Japan	2015-01-01
The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients	Drug:Rosuvastatin/Ezetimibe	Unknown status	Hypercholesterolemia	Phase 3	Korea, Republic of	2014-07-01
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD	Drug:EZ-Urso combination therapy	Terminated	Nonalcoholic Fatty Liver Disease (NAFLD)	Phase 2	United States	2014-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels	Drug:Ezetimibe;Drug:Cholecalciferol;Other:Placebo	Completed	Vitamin D Deficiency	Phase 4	Brazil	2014-10-01
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol	Drug:Evacetrapib;Drug:Atorvastatin;Drug:Ezetimibe;Drug:Placebo	Terminated	Hyperlipidemia	Phase 3	United States;Puerto Rico	2014-10-01
Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty	Drug:Atorvastatin;Drug:Rosuvastatin;Drug:Rosuvastatin;Drug:Ezetimibe;Drug:placebo	Terminated	Stable Coronary Artery Disease Undergoing PCI	Phase 3	Italy	2010-05-01
Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy	Drug:calcined magnesia;Drug:Ezetimibe/simvastatin;Drug:Rosuvastatin	Completed	Oxidative Stress;Diabetic Polyneuropathy	Phase 2	Mexico	2012-02-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe	Drug:Rosuvastatin 20mg;Drug:Ezetimibe 10mg;Drug:Rosuvastatin 20mg + Ezetimibe 10mg	Completed	Healthy	Phase 1	Korea, Republic of	2014-06-01
Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection	Drug:Ezetimibe	Recruiting	Chronic Hepatitis C	Phase 1	Chile	2013-10-01
The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients	Drug:Ezetimibe	Completed	Dyslipidemia;Transplants	Phase 4	Slovenia	2014-04-01
Plant Sterols Effect on Previous Statin Therapy	Other:Ezetimibe + plant sterols;Drug:Ezetimibe;Dietary Supplement:Plant sterols	Completed	Coronary Artery Disease	Phase 2/Phase 3	Brazil	2006-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Dose Ranging Study Of Bococizumab (PF-04950615 ; RN316) In Hypercholesterolemic Japanese Subjects	Drug:Bococizumab (PF-04950615;RN316);Drug:Bococizumab (PF-04950615;RN316);Drug:Bococizumab (PF-04950615;RN316);Drug:Placebo;Drug:Ezetimibe;Drug:Bococizumab (PF-04950615;RN316);Drug:Bococizumab (PF-04950615;RN316);Drug:Bococizumab (PF-04950615;RN316);Drug:Placebo	Completed	Hypercholesterolemia	Phase 2	Japan	2014-03-01
Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe	Drug:NVP-1205;Drug:rosuvastatin and ezetimibe	Completed	Dyslipidemia	Phase 1	Korea, Republic of	2014-02-01
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3	Drug:Part A, Atorvastatin;Other:Part A, Placebo (administered orally);Drug:Part B, Evolocumab;Other:Part B, Placebo (administered orally);Drug:Part B, Ezetimibe;Other:Part B, Placebo (administered subcutaneously);Drug:Part C, Evolocumab	Active, not recruiting	Hyperlipidemia	Phase 3	United States;Canada;Australia;Czech Republic;Denmark;France;Germany;Italy;Netherlands;New Zealand;Norway;South Africa;United Kingdom	2013-12-01
Cholesterol-lowering Effects of nutraceuticals Versus Ezetimibe in Statin-intolerant Patients	Drug:Ezetimibe;Dietary Supplement:Nutraceuticals	Not yet recruiting	Coronary Artery Disease	Phase 4	Italy	2014-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis	Drug:Ezetimibe	Completed	Non Alcoholic Steatohepatitis	Phase 2	United States	2013-01-01
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2	Biological:Evolocumab;Drug:Placebo to Evolocumab;Drug:Ezetimibe;Drug:Placebo to Ezetimibe	Completed	Hyperlipidemia	Phase 3	United States;Canada;Australia;Belgium;Denmark;France;Germany;Hong Kong;Netherlands;Poland;South Africa;Spain;Switzerland;United Kingdom	2013-01-01
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2	Biological:Evolocumab;Drug:Ezetimibe;Drug:Placebo to Evolocumab;Drug:Placebo to Ezetimibe;Drug:Atorvastatin;Drug:Rosuvastatin;Drug:Simvastatin	Completed	Hyperlipidemia	Phase 3	United States;Canada;Australia;Belgium;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom	2013-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2	Biological:Evolocumab;Drug:Ezetimibe;Biological:Placebo to Evolocumab;Other:Placebo to Ezetimibe	Completed	Hyperlipidemia	Phase 3	United States;Canada;Australia;Belgium;Denmark;France;Korea, Republic of;South Africa;Taiwan;Turkey	2013-01-01
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)	Drug:Alirocumab;Drug:Rosuvastatin;Drug:Ezetimibe;Drug:Placebo	Completed	Hypercholesterolemia	Phase 3	United States;Canada;Australia;France;Germany;Italy;Mexico;Spain;United Kingdom	2012-11-01
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)	Drug:Alirocumab;Drug:Atorvastatin;Drug:Ezetimibe;Drug:Rosuvastatin;Drug:Placebo	Completed	Hypercholesterolemia	Phase 3	United States;Canada;Australia;France;Germany;Italy;Mexico;Spain;United Kingdom	2012-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects	Drug:Alirocumab;Drug:Ezetimibe;Drug:Placebo;Drug:Fenofibrate	Completed	Hypercholesterolemia	Phase 1	France	2012-11-01
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)	Drug:Atorvastatin;Drug:Ezetimibe;Drug:Alirocumab;Drug:Placebo	Active, not recruiting	Hypercholesterolemia	Phase 3	United States;Canada;Austria;France;Israel;Italy;Norway;United Kingdom	2012-09-01
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis	Drug:Ezetimibe;Behavioral:Lifestyle	Unknown status	•Non-alcoholic Steatohepatitis (NASH)	Phase 4	Italy	2013-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients	Drug:ETC-1002;Drug:Ezetimibe	Completed	Hypercholesterolemia	Phase 2	United States	2013-09-01
Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe / Simvastatin (Vytorin®) Assessed by Virtual Histology - Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome	Device:Zotalolimus Eluting Stent;Device:Everolimus eluting stent;Drug:Ezetimibe 10mg & Simvastatin 40mg;Drug:Pravastatin 20mg	Completed	Acute Coronary Syndrome	Phase 4	Korea, Republic of	2009-11-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study	Drug:Ezetimibe;Drug:Placebo	Completed	Metabolic Syndrome X	Phase 3	Canada	2013-06-01
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia	Drug:Alirocumab;Drug:Ezetimibe;Drug:Placebo (for Alirocumab);Drug:Placebo (for Ezetimibe)	Completed	Hypercholesterolemia	Phase 3	United States;Belgium;Finland;Netherlands	2012-07-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)	Drug:Alirocumab;Drug:Placebo (for alirocumab);Drug:Ezetimibe;Drug:Placebo (for ezetimibe);Drug:Lipid Modifying Therapy (LMT)	Completed	Hypercholesterolemia	Phase 3	United States;Canada;Denmark;France;Hungary;Israel;Korea, Republic of;Russian Federation;South Africa;Ukraine	2012-08-01
A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)	Drug:Ezetimibe;Drug:Placebo	Completed	Hypercholesterolemia	Phase 4		2012-07-02
Physiological Study of Human Cholesterol Metabolism and Excretion	Drug:Ezetimibe	Completed	Coronary Heart Disease;Cardiovascular Disease;Dyslipidemia;Disorder of Cholesterol Metabolism	Phase 1	United States	2014-01-01
Acotral® Versus Zetia® Ezetimibe Bioequivalence Study.	Drug:10mg Ezetimibe;Drug:10mg Ezetimibe - wash out period	Completed	Hypercholesterolemia	Phase 1	India	2012-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderately High and High Risk Participants (MK-0653A-406)	Drug:Ezetimibe/simvastatin;Drug:Other Statin	Withdrawn	Dyslipidemia	Phase 4		2013-03-01
Sitosterolemia Metabolism	Drug:Ezetimibe	Active, not recruiting	Sitosterolemia		Canada	2012-04-01
Durable Effect of PCSK9 Antibody Compared with Placebo Study	Biological:Evolocumab;Biological:Placebo;Drug:Atorvastatin;Drug:Ezetimibe;Other:Diet Only	Completed	Hypercholesterolemia	Phase 3	United States;Canada;Australia;Austria;Belgium;Czech Republic;Denmark;Hungary;South Africa	2012-01-01
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients	Drug:Ezetimibe;Drug:Nutraceuticals	Unknown status	Coronary Artery Disease	Phase 4	Italy	2013-01-01
Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe	Drug:Simvastatin 80 mg;Drug:Sim10/Eze10;Drug:Placebo	Completed	Type 2 Diabetes;Inflammation		Germany	2004-04-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia	Drug:Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.;Drug:Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.	Completed	Hypercholesterolemia;Dyslipidemia	Phase 3	Brazil	2013-03-01
Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.	Drug:Ezetimibe;Drug:Placebo	Completed	ST-Segment Elevation Myocardial Infarction	Phase 4	Denmark	2011-06-01
Effect of Ezetimibe or Simvastatin or Both on Low Density Lipoprotein - Subfractions in Patients With Type 2 Diabetes	Drug:ezetimibe;Drug:simvastatin;Drug:Ezetimibe 10/Simvastatin 20	Completed	Diabetes Mellitus Type 2;Hypercholesterolemia	Phase 4	Germany	2007-11-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)	Drug:Ezetimibe	Completed	Hypercholesterolemia			2009-05-01
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels	Biological:Evolocumab;Drug:Ezetimibe;Other:Placebo to Evolocumab	Completed	Hyperlipidemia	Phase 2	United States;Canada;Australia;Belgium;Denmark	2011-07-01
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects	Biological:Evolocumab;Drug:Ezetimibe;Other:Placebo to Evolocumab	Completed	Hyperlipidemia	Phase 2	United States;Canada;Australia;Belgium;Denmark;Finland;Spain;Sweden	2011-07-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study to Evaluate the Effectiveness of Ezetimibe /Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)	Drug:Atorvastatin;Drug:Ezetimibe;Drug:Ezetimibe/atorvastatin;Drug:Placebo to atorvastatin;Drug:Placebo to ezetimibe;Drug:Placebo to ezetimibe/atorvastatin	Completed	Hypercholesterolemia	Phase 3		2011-09-01
A Study to Evaluate the Effectiveness of Ezetimibe /Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)	Drug:Atorvastatin;Drug:Ezetimibe;Drug:Ezetimibe/atorvastatin;Drug:Placebo to atorvastatin;Drug:Placebo to ezetimibe;Drug:Placebo to ezetimibe/atorvastatin	Completed	Hypercholesterolemia	Phase 3		2011-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe	Drug:simvastatin, combined with simvastatin ezetimibe, placebo	Unknown status	Endothelial Function		Brazil	2010-03-01
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)	Drug:Ezetimibe;Drug :Ezetimibe/atorvastatin 10mg/10mg FDC;Drug:Atorvastatin 10mg;Drug:Atorvastatin 80mg;Drug:Ezetimibe/atorvastatin 10mg/80mg FDC	Completed	Hyperlipidemia	Phase 1		2011-02-01
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK129263 Alone and With Atorvastatin	Drug:10mg atorvastatin;Drug:80mg atorvastatin;Drug:GSK1292263 Placebo;Drug:100mg GSK1292263;Drug:300mg GSK1292263;Drug:800mg GSK1292263;Drug:100mg ezetimibe;Other:Washout	Completed	Dyslipidaemias	Phase 2	United States	2010-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes	Drug:simvastatin/ezetimibe;Drug:atorvastatin 20mg	Unknown status	Type 2 Diabetes Mellitus Without Insulin Treatment	Phase 4	Korea, Republic of	2010-09-01
Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients		Completed	Dyslipidemia		Mexico	2009-04-01
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study) (MK-0653C-162)	Drug:ezetimibe 10 mg;Drug:atorvastatin;Drug:Comparator:rosuvastatin	Completed	Hypercholesterolemia	Phase 3		2010-07-01
Effect of Simvastatin and Ezetimibe on Lipid and Inflammation	Drug:Simvastatin;Drug:Ezetimibe;Drug:Combination Simvastatin plus Ezetimibe	Completed	Prediabetes;Hypercholesterolemia;Inflammation;Cardiovascular Risk		Brazil	2005-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Atorvastatin Plus Ezetimibe on Coronary Plaque Progression	Drug:atorvastatin;Drug:atorvastatin plus ezetimibe	Unknown status	Coronary Artery Disease	Phase 4	China	2010-01-01
An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)		Completed	Cancer			2010-03-01
The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome	Drug:Ezetimibe	Unknown status	Coronary Artery Disease	Phase 4	Japan	2010-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound	Drug:Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe];Drug:Lipitor (Atorvastatin) monotherapy	Completed	Hypercholesterolemia;Coronary Artery Disease	Phase 4	Japan	2010-01-01
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment	Drug:Ezetimibe	Completed	Diabetes Mellitus;Renal Impairment	Phase 4	Sweden	2006-01-01
Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol	Drug:ezetimibe	Completed	Coronary Artery Disease;Diabetes	Phase 4	Lebanon	2008-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.	Drug:Simvastatin;Drug:Vytorin;Drug:Placebo;Drug:Ezetimibe	Unknown status	Metabolic Syndrome	Phase 4	United States	2009-10-01
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia	Drug:Rosuvastatin;Drug:Ezetimibe	Unknown status	Hypercholesterolemia	Phase 4	United States	2009-09-01
Ezetimibe in Patients Hyporesponsive to Statins	Drug:Ezetimibe;Drug:Atorvastatin	Terminated	High Cholesterol;Coronary Artery Disease	Phase 3	United States	2009-09-01
Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels	Dietary Supplement:Flax seed oil (ALA);Drug:Ezetimibe	Completed	Hypercholesterolemia;Hyperlipidemia		Canada	2009-07-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low-Density Lipoprotein (LDL)	Drug:SIMVASTATIN 40 mg;Drug:SIMVASTATIN/EZETIMIBE 10/10 mg	Completed	Hypercholesterolemia	Phase 4	Greece	2009-06-01
Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)	Drug:Ezetrol (Ezetimibe);Drug:Vytorin (Ezetimibe + Simvastatin)	Withdrawn	Atherosclerosis		Korea, Republic of	2011-09-01
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)	Drug:Vytorin (R) (Ezetimibe + Simvastatin)	Completed	Hypercholesterolemia			2006-11-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets	Drug:Ezetimibe;Drug :Rosuvastatin (standard care)	Completed	Hypercholesterolemia;HIV Infections		Canada	2009-06-01
Additive Effect of Ezetimibe Upon Simvastatin in During Myocardial Infarction	Drug:Simvastatin;Drug:Ezetimibe-Simvastatin	Completed	Myocardial Infarction	Phase 4	Brazil	2009-05-01
Effect of Diabetes Mellitus on Cholesterol Metabolism	Drug:simvastatin or ezetimibe	Completed	Type 1 Diabetes Mellitus;Type 2 Diabetes Mellitus;Hypercholesterolemia		United States	2008-08-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027) (COMPLETED)	Drug:Ezetimibe;Drug:Atorvastatin;Drug:Atorvastatin;Drug:Rosuvastatin	Completed	Primary Hypercholesterolemia	Phase 4		2009-02-01
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)	Drug:ezetimibe;Drug:Placebo	Completed	Primary Hypercholesterolemia	Phase 3		2009-05-01
Phytosterols, Ezetimibe, and Cholesterol Metabolism	Drug:Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols	Completed	Hypercholesterolemia;Coronary Heart Disease		United States	2009-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Ezetimibe /Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133) (COMPLETED)	Drug:ezetimibe (+) simvastatin;Drug:simvastatin 40 mg or atorvastatin 20 mg;Drug:Rosuvastatin;Drug:atorvastatin 10 mg or simvastatin 20 mg	Completed	Cardiovascular Disorder;Diabetes Mellitus	Phase 3		2009-04-01
Ezetimibe /Simvastatin Combination in Proteinuric Nephropathy	Drug:simvastatin;Drug:EZE/simvastatin	Unknown status	Hypercholesterolemia;Chronic Nephropathy	Phase 4	Italy	2008-11-01
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients	Drug:ezetimibe;Drug:fenofibrate;Drug:pravastatin	Unknown status	HIV;Hyperlipidemia;HIV Infections	Phase 4	Italy	2009-03-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment	Drug:simvastatin;Drug:ezetimibe/simvastatin	Completed	Metabolic Syndrome	Phase 4	United States	2009-01-01
The Postprandial Endothelial Function After Combination of Ezetimibe and simvastatin Study	Drug:Simvastatin;Drug:Simvastatin/Ezetimibe	Completed	Metabolic Syndrome	Phase 4	Netherlands; Spain	2009-04-01
Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk	Drug:fluvastatin;Drug:Fluvastatin plus ezetimibe	Completed	Hypercholesterolemia	Phase 4	Austria	2005-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2	Drug:Ezetrol (ezetimibe) multiple dose;Drug:Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose;Drug:Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose;Drug:Sustiva (efavirenz) single dose	Completed	Pharmacokinetic s;Drug Interactions;Pharmacodynamics;Intestinal Transporter Expression	Phase 1	Germany	2009-03-01
Effects of Ezetimibe on the Absorption of Oxidized Cholesterol	Drug:ezetimibe	Completed	Hypercholesterolemia	Phase 4	United States	2006-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)	Drug:Comparator: rosuvastatin 5 mg + ezetimibe 10 mg;Drug:Comparator: rosuvastatin 10 mg;Drug:Comparator: rosuvastatin 10 mg + ezetimibe 10 mg;Drug:Comparator: rosuvastatin 20 mg	Completed	Hypercholesterolemia	Phase 3		2008-11-01
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1) (COMPLETED)	Drug:ezetimibe/simvastatin 10/40;Drug:atorvastatin 40 mg;Drug:atorvastatin 20 mg	Completed	Hypercholesterolemia	Phase 3		2008-11-01
Raltegravir and Ezetimibe PK Study	Drug:Raltegravir and ezetimibe;Drug:Ezetimibe and raltegravir	Completed	HIV	Phase 1	United Kingdom	2008-06-01
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)	Drug:Ezetimibe 10 mg;Drug:Ezetimibe 5 mg	Completed	Hypercholesterolemia		United States	2007-07-01
Ezetrol Post-Marketing Study	Drug:simvastatin;Drug:Ezetimibe	Completed	Hyperlipidemia	Phase 4		2006-07-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors	Drug:ezetimibe/simvastatin 10/20 mg + placebo;Drug:ezetimibe/simvastatin 10/20 mg + MK0524A	Withdrawn	Cardiovascular Diseases;Hyperlipidemia	Phase 4		2009-11-01
Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients (MK0653A-168)	Drug:valsartan;Drug:pravastatin;Drug:simvastatin;Drug:ezetimibe (+) simvastatin	Terminated	Hypertension	Phase 3		2008-01-01
Vytorin on Carotid Intima-media Thickness and Overall Rigidity	Drug:ezetimibe (+) simvastatin;Drug:simvastatin;Drug:pravastatin	Completed	Cardiovascular Diseases	Phase 4		2005-04-01
Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <> (Study P05464)	Drug:Ezetimibe;Drug:Statin	Completed	Coronary Heart Disease;Hypercholesterolemia			2008-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171) (COMPLETED)	Drug:Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate	Completed	Dyslipidemia			2007-05-01
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	Drug:simvastatin;Drug:ezetimibe;Drug:placebo	Unknown status	Acute Coronary Syndrome		Poland	2008-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)	Drug:Ezetimibe;Drug :Ezetimibe + other lipid-lowering medication(s)	Completed	Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia			2007-06-01
Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276) (COMPLETED)	Drug:ezetimibe;Drug :statin	Completed	Hypercholesterolemia			2006-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748) (COMPLETED)	Drug:Ezetimibe	Completed	Primary Hypercholesterolemia;Homozygous Familial Hypercholesterolemia			2006-03-01
A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)	Drug:Ezetimibe;Drug :Ezetimibe + other lipid-lowering medication(s)	Completed	Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia			2007-06-01
Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study	Drug:ezetimibe;Drug :Placebo	Completed	Hypercholesterolemia	Phase 4	United States	2008-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes	Drug:ezetimibe tablets;Drug:simvastatin tablets;Drug:placebo	Completed	Postprandial Lipemia;Type 2 Diabetes	Phase 4	Italy	2008-06-01
Effectiveness of Intensive Lipid Modification in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)	Drug:Ezetimibe;Drug:Niaspan;Drug:Statin therapy;Behavioral:Standard care;Drug:Aspirin;Drug:Clopidogrel;Drug:Placebo Niaspan;Drug:Placebo Ezetimibe;Procedure:Percutaneous transluminal angioplasty (PTA)	Completed	Peripheral Arterial Disease	Phase 4	United States	2004-04-01
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe	Drug:ABT-335;Drug:Atorvastatin;Drug:Ezetimibe	Completed	Pharmacokinetics	Phase 1	United States	2008-04-01
Risk Reduction in Coronary Heart Disease	Behavioral:smoking cessation;Drug:beta blocker, diuretics, ACEI, ARB;;Drug:statins, ezetimibe;Behavioral:training;Biological:influenza vaccine;Drug:metformin, glimepiride, insulin;Behavioral:weight reduction	Recruiting	Coronary Heart Disease		Norway	2007-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe	Drug:Ezetimibe and placebo;Drug:Eprotirone and ezetimibe	Completed	Hypercholesterolemia	Phase 2	Sweden	2008-04-01
INDians Followed for INTensive Lipid Lowering Treatment and Its safety	Drug:ezetimibe;Drug:Comparator: Simvastatin 20, 40 and 80 mg;Drug:Comparator: Atorvastatin;Drug:Comparator: Rosuvastatin	Terminated	Hypercholesterolemia	Phase 3	Canada	2007-08-01
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172) (COMPLETED)	Drug:ezetimibe (+) simvastatin	Completed	Hypercholesterolemia	Phase 4		2007-08-01
Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)	Drug:Ezetimibe;Drug:atorvastatin	Completed	Hypercholesterolemia	Phase 3		2007-12-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962) (COMPLETED)	Drug: SCH 58235; Drug: pitavastatin	Completed	Hypercholesterolemia	Phase 1		2004-03-01
Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)	Drug: Ezetimibe + Simvastatin; Drug: Simvastatin	Completed	Hypercholesterolemia; Atherosclerosis	Phase 4		2003-09-01
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)	Drug: Ezetimibe + Atorvastatin; Drug: Atorvastatin	Completed	Hypercholesterolemia; Atherosclerosis	Phase 4		2003-09-01
Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)	Drug: Ezetimibe; Drug: Simvastatin	Completed	Hypercholesterolemia	Phase 3		2007-12-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg	Drug:Rosuvastatin;Drug:Ezetimibe	Completed	Hypercholesterolemia;Coronary Heart Disease;Atherosclerosis	Phase 3		2004-06-01
MD Ezetimibe Cyclosporine Interaction (0653-057)	Drug:ezetimibe;Drug:Comparator:cyclosporine	Completed	Cholesterol	Phase 1		2003-11-01
Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152) (COMPLETED)	Drug:ezetimibe;Drug:statins	Completed	Hypercholesterolemia	Phase 4		2005-05-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI) (0653A-150)	Drug:Ezetimibe;Drug:simvastatin	Completed	Cardiovascular Disorder	Phase 4		2005-02-01
Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)	Drug:ezetimibe;Drug:simvastatin;Drug:Placebo (Unspecified)	Completed	Hypercholesterolemia	Phase 4		2003-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)	Drug:Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin);Drug:Double Statin (simvastatin, atorvastatin, or pravastatin)	Completed	Hypercholesterolemia	Phase 4		2005-12-01
A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050) (COMPLETED)	Drug:ezetimibe;Drug:Comparator: Placebo (unspecified);Drug:simvastatin	Completed	Cholesterol	Phase 3		2003-07-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141) (COMPLETED)	Drug:ezetimibe	Completed	Lipid Metabolism Disorder	Phase 4		2004-09-01
Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)	Drug:ezetimibe (+) simvastatin	Completed	Hyperlipidemia	Phase 3		2005-11-01
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)	Drug:Ezetimibe;Drug:Placebo	Completed	Hypercholesterolemia;Atherosclerosis	Phase 3		2004-01-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Effect of Ezetimibe Plus Simvastatin in on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)	Drug:Ezetimibe + Simvastatin;Drug:Simvastatin;Drug:Placebo	Terminated	Hypercholesterolemia;Atherosclerosis	Phase 3		2003-10-01
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)	Drug:Rosuvastatin;Drug:Ezetimibe + Atorvastatin;Drug:Double Atorvastatin	Terminated	Hypercholesterolemia;Atherosclerosis;Coronary Artery Disease	Phase 4		2004-09-01
Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)	Drug:Ezetimibe;Drug:Placebo	Completed	Atherosclerosis;Hypercholesterolemia;Coronary Heart Disease	Phase 4		2003-04-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)	Drug:Ezetimibe + Rosuvastatin;Drug:Rosuvastatin;Drug:Placebo;Drug:Ezetimibe	Completed	Hypercholesterolemia;Atherosclerosis	Phase 1		2003-03-01
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)	Drug:Ezetimibe;Drug:Placebo	Terminated	Hypercholesterolemia;Atherosclerosis	Phase 4		2004-01-01
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757) (COMPLETED)	Drug:Ezetimibe + Simvastatin;Drug:Simvastatin;Drug:Ezetimibe	Completed	Hypercholesterolemia	Phase 3		2004-06-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)	Drug:Ezetimibe + Atorvastatin;Drug:Atorvastatin	Completed	Hypercholesterolemia;Atherosclerosis;Coronary Artery Disease	Phase 3		2003-05-01
Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)	Drug:Ezetimibe + Simvastatin;Drug:Simvastatin	Completed	Hypercholesterolemia;Atherosclerosis	Phase 4		2003-10-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood	Drug:ABT-335;Drug:placebo;Drug:atorvastatin;Drug:ezetimibe	Completed	Dyslipidemias;Coronary Heart Disease;Combined (Atherogenic) Dyslipidemia;Mixed Dyslipidemia	Phase 3	United States	2008-02-01
The Influence of Ezetimibe on Gallbladder Function	Drug:ezetimibe;Drug:Placebo	Withdrawn	Chronic Acalculous Cholecystitis		United States	2009-08-01
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects	Drug:1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany;Drug:1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany;Drug:1 tablet Ezetrol(R) + 1 capsules Prograf(R)	Completed	Pharmacokinetics;Drug Interactions;Hypercholesterolemia;Immunosuppression	Phase 1	Germany	2007-09-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects	Drug:1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany;Drug:1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany;Drug:1 tablet Ezetrol(R) + 1 tablet Rapamune(R)	Completed	Pharmacokinetics;Drug Interactions;Hypercholesterolemia;Immunosuppression	Phase 1	Germany	2007-04-01
Comprehensive Magnetic Resonance of Peripheral Arterial Disease	Drug:Simvastatin;Drug:Ezetimibe;Drug:Simvastatin/Ezetimibe	Completed	Peripheral Artery Disease		United States	2006-01-01
A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet	Drug:simvastatin 20 mg/ezetimibe	Completed	Hyperlipidemia	Phase 2/Phase 3		2006-04-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
Vascular Effects of Ezetimibe /Simvastatin and Simvastatin on Atherosclerosis	Drug:Simvastatin (Zocor);Drug:10mg/10mg of Ezetimibe/Simvastatin (Vytorin)	Completed	Atherosclerosis	Phase 4	Taiwan	2007-09-01
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS	Drug:AEGR-733;Drug:placebo;Drug:AEGR-733;Drug:AEGR-733;Drug:AEGR-733 and atorvastatin;Drug:AEGR-733 and fenofibrate;Drug:AEGR-733 and ezetimibe	Completed	Hyperlipidemia	Phase 2	United States	2007-10-01
Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE) (P02578)	Drug:ezetimibe (plus simvastatin);Drug:placebo (plus simvastatin)	Completed	Atherosclerosis;Hypercholesterolemia;Hyperlipoproteinemia Type II	Phase 3		2002-06-01
Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021) (COMPLETED)	Drug:MK0653, ezetimibe / Duration of Treatment: 30 Weeks;Drug:Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks	Completed	Diabetes Mellitus, Type 2	Phase 3		2001-12-01

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023) (COMPLETED)	Drug:MK0653, ezetimibe / Duration of Treatment: 27 Weeks;Drug:MK0733 , simvastatin / Duration of Treatment: 27 Weeks;Drug:Comparator: simvastatin / Duration of Treatment: 27 Weeks	Completed	Coronary Disease	Phase 3		2002-01-01
The Clinical Study of Pitavastatin in Treatment for Group of Mild to Moderate Alzheimer's Disease	Drug:Pitavastatin;Drug:cholesterol-lowering medicine other than statin(e.g.,Ezetimibe, Colestimide)	Terminated	Alzheimer Disease;Hypercholesterolemia		Japan	2007-11-01
Eze/Simva Switch Study in Diabetics (0653A-807)	Drug:MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks;Drug:Comparator: atorvastatin / Duration of Treatment: 6 Weeks	Completed	Diabetes Mellitus, Type 2	Phase 3		2005-01-19

注册题目	干预措施	招募状态	研究疾病	研究阶段	国家	开始时间
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe /Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)	Drug:Atorvastatin 10 mg;Drug:Ezetimibe 10 mg/simvastatin 20 mg;Drug:Atorvastatin 20 mg;Drug:Ezetimibe 10 mg/simvastatin 40 mg;Drug:Atorvastatin 40 mg	Completed	Hypercholesterolemia	Phase 3		2007-11-01
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe	Drug:Rosuvastatin (Crestor);Drug:Ezetimibe;Drug:Simvastatin	Completed	Hypercholesterolemia;Coronary Heart Disease;Atherosclerosis	Phase 3	United States;Argentina;Brazil;Chile;Colombia;Lithuania;Netherlands;Peru;Venezuela	2007-08-01